History

Bio-Tissue, Inc. founded in 1997, has become the industry leader in regenerative tissue engineering fueled by its genuine desire to provide the highest quality tissue product and the highest level of patient care.  In the search for a better surgical alternative,  the extraordinary qualities of amniotic membrane were discovered.  For a long time, there had been an unanswered need for both a non-immunogenic tissue replacement and for tissue regeneration. Initial research began in the 1980’s with  Dr. Scheffer C.G. Tseng and his team who believed that the solution lay in utilizing the regenerative properties of amniotic membrane.  In the late 1990’s, Dr. Tseng  introduced the use of amniotic membrane for ocular surface reconstruction by using a novel method of processing and preservation.

Based on a highly innovative and dynamic platform technology, Bio-Tissue’s talented research team developed its primary product, AmnioGraft®: the only tissue graft designated by the FDA as homologous for promoting ophthalmic wound healing while suppressing scarring and inflammation.  Harnessing amniotic membrane’s mechanisms of action, the Bio-Tissue Method allows AmnioGraft® to retain the natural properties of amniotic membrane without the risk of rejection.  AmnioGraft® acts as more than just a physical graft as it actively accelerates healing of the surgical space by facilitating re-epithelialization while simultaneously suppressing scar formation, inflammation, and pain.  This makes AmnioGraft® the ideal graft for surgical use.